2010 versus the 2000 consensus criteria in patients with normalised insulin‐like growth factor 1 after transsphenoidal surgery has high predictive values for long‐term recurrence‐free survival in acromegaly - Shen - 2021

Pharmacogenomics of insulin-like growth factor-I generation during GH treatment in children with GH deficiency or Turner syndrome

Characteristics of Gut Microbiota in Patients with GH-Secreting Pituitary Adenoma

The p300 Inhibitor A-485 Exerts Antitumor Activity in Growth Hormone Pituitary Adenoma. - Abstract - Europe PMC

Assessment of sFRP4 as a bio-marker for predicting aggressiveness and recurrence of growth hormone-secreting pituitary adenomas

Frontiers Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegaly

Assessment of sFRP4 as a bio-marker for predicting aggressiveness and recurrence of growth hormone-secreting pituitary adenomas

Acromegaly: pathogenesis, diagnosis, and management - ScienceDirect

PDF) Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegaly

Frontiers Erectile Dysfunction Is Associated With Excessive Growth Hormone Levels in Male Patients With Acromegaly

Diffuse Hormonal Systems - Endotext - NCBI Bookshelf

Diagnosis and Treatment of Acromegaly: An Update - Mayo Clinic Proceedings

Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future in: Endocrine-Related Cancer Volume 23 Issue 12 (2016)

2010 versus the 2000 consensus criteria in patients with normalised insulin‐like growth factor 1 after transsphenoidal surgery has high predictive values for long‐term recurrence‐free survival in acromegaly - Shen - 2021

Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance - Journal of Hepatology